Your browser doesn't support javascript.
loading
Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
Jacene, Heather A; Youn, Trisha; DiPiro, Pamela J; Hu, Jiani; Cheng, Su-Chun; Franchetti, Yoko; Shah, Hina; Bellon, Jennifer R; Warren, Laura; Schlosnagle, Emily; Nakhlis, Faina; Rosenbluth, Jennifer; Yeh, Eren; Overmoyer, Beth.
Afiliação
  • Jacene HA; Department of Imaging and Radiology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Electronic address: hjacene@bwh.harvard.edu.
  • Youn T; Department of Radiology, New York Presbyterian Hospital, New York, NY.
  • DiPiro PJ; Department of Imaging and Radiology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
  • Hu J; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
  • Cheng SC; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
  • Franchetti Y; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA.
  • Shah H; Department of Imaging and Radiology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
  • Bellon JR; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
  • Warren L; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
  • Schlosnagle E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Nakhlis F; Department of Surgery, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
  • Rosenbluth J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Yeh E; Department of Imaging and Radiology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
  • Overmoyer B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Clin Breast Cancer ; 19(2): 146-155, 2019 04.
Article em En | MEDLINE | ID: mdl-30584057
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Fluordesoxiglucose F18 / Neoplasias Inflamatórias Mamárias Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Fluordesoxiglucose F18 / Neoplasias Inflamatórias Mamárias Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Ano de publicação: 2019 Tipo de documento: Article